https://www.fool.com/investing/general/2003/09/30/biotech-rebirth.aspx
https://www.fool.com/investing/general/2004/02/10/the-psoriasis-wars.aspx
https://www.fool.com/investing/general/2003/12/09/telik-traps-new-cancer-pills.aspx
https://www.fool.com/investing/general/2004/03/23/genentechs-star-power.aspx
https://www.fool.com/investing/small-cap/2005/03/30/soothing-results-but-pain-for-investors.aspx
https://www.fool.com/investing/general/2004/01/13/vicurons-booster-shot.aspx
https://www.fool.com/investing/general/2004/03/16/sanofi-slimming-pill.aspx
https://www.fool.com/investing/general/2004/01/06/isis-2g-drug-shines.aspx
https://www.fool.com/investing/general/2004/02/03/big-break-for-a-small-biotech.aspx
https://www.fool.com/investing/general/2003/10/28/biotech-pain-killer.aspx
https://www.fool.com/news/take/2002/11/21/ciscos-dividend-debate-mft02112102.aspx
https://www.fool.com/investing/general/2004/01/27/pfizers-next-target.aspx
https://www.fool.com/investing/general/2004/03/02/genzymes-oncology-acquisitions.aspx
https://www.fool.com/investing/general/2003/11/24/decodes-new-code.aspx
https://www.fool.com/investing/general/2003/11/05/biotech-unclogs-arteries.aspx
https://www.fool.com/investing/general/2004/03/30/jumping-biotechs.aspx
https://www.fool.com/investing/general/2004/01/20/adolors-knockedout-drug.aspx
https://www.fool.com/investing/general/2004/02/17/antisense-making-sense.aspx
https://www.fool.com/investing/general/2003/09/19/introgen-rockets-on-trials.aspx
https://www.fool.com/investing/general/2003/11/03/bedside-biotechs.aspx
https://www.fool.com/investing/general/2003/12/02/hope-for-diabetics--and-investors.aspx
https://www.fool.com/investing/general/2004/03/09/sepracors-no-sleeper.aspx
https://www.fool.com/investing/general/2003/12/16/biotechs-next-phase.aspx
https://www.fool.com/investing/general/2003/12/23/an-undervalued-biotech.aspx
https://www.fool.com/investing/general/2004/02/24/cell-genesys-boosted.aspx
